Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Ref Title
TA167 Abdominal aortic aneurysm - endovascular stent-grafts: costing statement
TA182 Acute coronary syndrome - prasugrel: costing template
TA236 Acute coronary syndromes - ticagrelor: costing template
CG169 Acute kidney injury: costing statement
CG50 Acutely ill patients in hospital: costing report
CG50 Acutely ill patients in hospital: costing template
CG141 Acute upper GI bleeding: costing report
CG81 Advanced breast cancer: costing report
CG81 Advanced breast cancer: costing template
CG115 Alcohol dependence and harmful alcohol use: costing report
CG115 Alcohol dependence and harmful alcohol use: costing template
CG100 Alcohol-use disorders: physical complications: costing report
CG100 Alcohol-use disorders: physical complications: costing template
PH24 Alcohol-use disorders - preventing harmful drinking: costing report
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: costing template
TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: costing statement
CG114 Anaemia management in people with chronic kidney disease: costing report
CG114 Anaemia management in people with chronic kidney disease: costing template
CG134 Anaphylaxis: costing statement
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab: cost template
TA233 Ankylosing spondylitis - golimumab: costing statement
CG45 Antenatal and postnatal mental health: costing report
CG45 Antenatal and postnatal mental health: costing template
CG62 Antenatal care and diabetes in pregnancy: costing report
CG62 Antenatal care and diabetes in pregnancy: costing template
CG149 Antibiotics for early-onset neonatal infection: costing report
CG149 Antibiotics for early-onset neonatal infection: costing template
CG77 Antisocial personality disorder: costing report
CG77 Antisocial personality disorder: costing template
CG113 Anxiety: costing statement
CG113 Anxiety: costing template
TA95 Arrhythmia - implantable cardioverter defibrillators (ICDs) (review): analysis of cost impact
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab: costing statement
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44): costing statement
TA138 Asthma (in adults) - corticosteroids: costing statement
TA131 Asthma (in children) - corticosteroids: costing statement
TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): costing statement
CG57 Atopic eczema in children: costing report
CG57 Atopic eczema in children: costing template
CG36 Atrial fibrillation: cost impact report
CG36 Atrial fibrillation: costing template (England)
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban: costing template
TA249 Atrial fibrillation - dabigatran etexilate: costing template
TA197 Atrial fibrillation - dronedarone: costing template
CG72 Attention deficit hyperactivity disorder (ADHD): costing report
CG72 Attention deficit hyperactivity disorder (ADHD): costing template
CG142 Autism in adults: costing report
CG128 Autism in children and young people: costing statement
CG170 Autism - management of autism in children and young people: costing statement
CG102 Bacterial meningitis and meningococcal septicaemia: cost statement
CG106 Barrett's oesophagus - ablative therapy: costing statement
PH49 Behaviour change: individual approaches - Costing statement
PH6 Behaviour change - the principles for effective interventions: costing statement
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: costing statement
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer: costing statement
CG38 Bipolar disorder: costing report
CG38 Bipolar disorder: costing template
TA292 Bipolar disorder (children) - aripiprazole: costing statement
PH46 BMI and waist circumference - black, Asian and minority ethnic groups: costing statement
TA265 Bone metastases from solid tumours - denosumab: costing template
CG78 Borderline personality disorder (BPD): costing report
TA250 Breast cancer (advanced) - eribulin: costing statement
TA109 Breast cancer (early) - docetaxel: costing template and report
TA112 Breast cancer (early) - hormonal treatments: costing template and report
TA107 Breast cancer (early) - trastuzumab: costing template and report
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): costing statement
TA239 Breast cancer (metastatic) - fulvestrant: costing statement
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): costing statement
TA214 Breast cancer - bevacizumab (in combination with a taxane): costing statement
TA116 Breast cancer - gemcitabine: costing statement
PH1 Brief interventions and referral for smoking cessation: costing report
PH1 Brief interventions and referral for smoking cessation: costing template
CG132 Caesarean section: costing report
CG132 Caesarean section: costing template
TA191 cancer (advanced) - capecitabine: cost statement
TA183 Cervical cancer (recurrent) - topotecan: costing statement
CG95 Chest pain of recent onset: costing report
CG95 Chest pain of recent onset: costing template
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab: costing statement
CG53 Chronic fatigue syndrome / Myalgic encephalomyelitis: costing report
CG53 Chronic fatigue syndrome / Myalgic encephalomyelitis: costing template
CG108 Chronic heart failure: costing report
CG108 Chronic heart failure: costing template
TA267 Chronic heart failure - ivabradine: costing template
CG73 Chronic kidney disease: costing report
CG73 Chronic kidney disease: costing template
TA202 Chronic lymphocytic leukaemia - ofatumumab: costing statement
CG101 Chronic obstructive pulmonary disease (update): costing report
CG101 Chronic obstructive pulmonary disease (update): costing template
TA244 Chronic obstructive pulmonary disease - roflumilast: costing statement
CG86 Coeliac disease: cost report
CG86 Coeliac disease: cost template
CG118 Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas: costing statement
CG118 Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas: costing template
CG131 Colorectal cancer: costing report
CG131 Colorectal cancer: costing template
TA176 Colorectal cancer (first line) - cetuximab: costing template
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): costing statement
TA307 Colorectal cancer (metastatic) - aflibercept: costing statement
TA212 Colorectal cancer (metastatic) - bevacizumab: costing statement
TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab: costing statement
TA105 Colorectal cancer - laparoscopic surgery: costing template and report
CG123 Common mental health disorders: costing report
CG123 Common mental health disorders: costing template
PH9 Community engagement: costing statement
CG158 Conduct disorders in children and young people: costing report
CG158 Conduct disorders in children and young people: costing template
CG99 Constipation in children and young people: costing report
CG99 Constipation in children and young people: costing template
PH51 Contraceptive services with a focus on young people up to the age of 25: costing report
PH51 Contraceptive services with a focus on young people up to the age of 25: costing statement
PH51 Contraceptive services with a focus on young people up to the age of 25: costing template
TA152 Coronary artery disease - drug-eluting stents: cost template
CG83 Critical illness rehabilitation: costing report
CG83 Critical illness rehabilitation: costing template
CG152 Crohn's disease: costing statement
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40): costing template
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: costing statement
TA266 Cystic fibrosis - mannitol dry powder for inhalation: costing statement
CG103 Delirium: costing report
CG103 Delirium: costing template
CG42 Dementia: costing report
CG42 Dementia: costing template
CG42 Dementia: supplementary costing report and template
CG90 Depression in adults: costing statement
CG91 Depression in adults with a chronic physical health problem: costing statement
CG28 Depression in children and young people: cost impact report
CG28 Depression in children and young people: costing template (England)
DG10 DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: costing template
DG11 DG11 Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel: costing template
DG3 DG3 Computed tomography (CT) scanners for cardiac imaging - Somatom Definition Flash, Aquilion One, Brilliance iCT and Discovery CT750: costing statement
DG4 DG4 Adjunctive colposcopy technologies for examination of the uterine cervix - DySIS and the Niris Imaging: costing template
DG5 DG5 SonoVue (sulphur hexafluoride microbubbles) - contrast agent for contrast-enhanced ultrasound imaging of the liver: costing template
DG6 DG6 Depth of anaesthesia monitors (E-Entropy, BIS and Narcotrend): costing statement
DG8 DG8 Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer: costing template
TA248 Diabetes (type 2) - exenatide (prolonged release): costing statement
TA203 Diabetes (type 2) - liraglutide: costing template
CG63 Diabetes in pregnancy: costing report
CG63 Diabetes in pregnancy: costing template
TA151 Diabetes - insulin pump therapy: costing template
CG119 Diabetic foot problems - inpatient management: costing statement
TA271 Diabetic macular oedema - fluocinolone acetonide intravitreal implant: costing statement
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271): costing template
CG84 Diarrhoea and vomiting in children under 5: costing statement
PH50 Domestic violence and abuse - how services can respond effectively: costing statement
CG93 Donor breast milk banks: costing statement
CG52 Drug misuse: psychosocial interventions and opioid detoxification: costing report
CG51 Drug misuse: psychosocial interventions and opioid detoxification: costing report
CG52 Drug misuse: psychosocial interventions and opioid detoxification: costing template
CG51 Drug misuse: psychosocial interventions and opioid detoxification: costing template
TA114 Drug misuse - methadone and buprenorphine: costing template and costing report
TA115 Drug misuse - naltrexone: costing statement
CG80 Early and locally advanced breast cancer: costing report
CG80 Early and locally advanced breast cancer: costing template
CG154 Ectopic pregnancy and miscarriage: costing report
CG154 Ectopic pregnancy and miscarriage: costing template
TA177 Eczema (chronic) - alitretinoin: costing template
DG9 Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: costing statement
CG137 Epilepsy: costing statement
TA232 Epilepsy (partial) - retigabine (adjuvant): costing statement
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma: costing statement
CG49 Faecal incontinence: costing report
CG49 Faecal incontinence: costing template
CG161 Falls: costing statement
CG164 Familial breast cancer: costing report
CG41 Familial breast cancer: costing report (based on the original recommendations)
CG164 Familial breast cancer: costing template
CG71 Familial hypercholesterolaemia: costing report
CG71 Familial hypercholesterolaemia: costing template
CG156 Fertility: costing report
CG156 Fertility: costing template
CG160 Feverish illness in children: costing statement
TA243 Follicular lymphoma - rituximab (review): costing statement
CG116 Food allergy in children and young people: costing report
PH2 Four commonly used methods to increase physical activity: costing report
PH2 Four commonly used methods to increase physical activity: costing template
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: costing template
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib: costing statement
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant): costing statement
TA179 Gastrointestinal stromal tumours - sunitinib: costing template
CG85 Glaucoma: costing report
CG85 Glaucoma: costing template
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: costing template
TA291 Gout (tophaceous, severe debilitating, chronic) - pegloticase: costing statement
TA128 Haemorrhoid - stapled haemorroidopexy: costing statement
CG150 Headaches: costing report
CG150 Headaches: costing template
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab: costing template
TA145 Head and neck cancer - cetuximab: costing template
CG176 Head injury: costing report
CG176 Head injury: costing template
TA166 Hearing impairment - cochlear implants: costing tool
TA120 Heart failure - cardiac resynchronisation: costing template
CG44 Heavy menstrual bleeding: costing report
CG44 Heavy menstrual bleeding: costing template
CG165 Hepatitis B (chronic): costing template
PH43 Hepatitis B and C - ways to promote and offer testing: costing report
PH43 Hepatitis B and C - ways to promote and offer testing: costing template
TA153 Hepatitis B - entecavir: costing statement
TA154 Hepatitis B - telbivudine: costing statement
TA173 Hepatitis B - tenofovir disoproxil fumarate: costing statement
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin: costing statement
TA253 Hepatitis C (genotype 1) - boceprevir: costing template
TA252 Hepatitis C (genotype 1) - telaprevir: costing template
TA200 Hepatitis C - peginterferon alfa and ribavirin: costing template
TA106 Hepatitis C - peginterferon alfa and ribavirin: costing template and report
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): costing statement
CG124 Hip fracture: costing report
CG124 Hip fracture: costing template
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children: costing template and report
TA132 Hypercholesterolaemia - ezetimibe: costing statement
CG130 Hyperglycaemia in acute coronary syndromes: costing statement
TA117 Hyperparathyroidism - cinacalcet: costing statement
CG157 Hyperphosphataemia in chronic kidney disease: costing report
CG157 Hyperphosphataemia in chronic kidney disease: costing template
CG127 Hypertension: costing report
CG127 Hypertension: costing template
CG107 Hypertension in pregnancy: costing report
CG107 Hypertension in pregnancy: costing template
TA164 Hyperuricaemia - febuxostat: costing template
PH15 Identifying and supporting people most at risk of dying prematurely: costing statement
CG163 Idiopathic pulmonary fibrosis: costing report
CG163 Idiopathic pulmonary fibrosis: costing template
TA282 Idiopathic pulmonary fibrosis - pirfenidone: costing template
PH33 Increasing the uptake of HIV testing among black Africans in England: costing report
PH33 Increasing the uptake of HIV testing among black Africans in England: costing template
PH34 Increasing the uptake of HIV testing among men who have sex with men: costing report
PH34 Increasing the uptake of HIV testing among men who have sex with men: costing template
CG70 Induction of labour: costing statement
CG139 Infection control: costing statement
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: cost template
TA168 Influenza - zanamivir, amantadine and oseltamivir (review): costing statement
PH4 Interventions to reduce substance misuse among vulnerable young people: costing report
PH4 Interventions to reduce substance misuse among vulnerable young people: costing template
PH4 Interventions to reduce substance misuse among vulnerable young people: implementation and costing statement
CG55 Intrapartum care: costing statement
CG174 Intravenous fluid therapy in adults in hospital: costing statement
CG61 Irritable bowel syndrome: costing report
CG61 Irritable bowel syndrome: costing template
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab: costing report and template
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab: costing template & report
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib: costing statement
TA299 Leukaemia (chronic myeloid) - bosutinib: costing statement
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): costing statement
TA216 Leukaemia (lymphocytic) - bendamustine: costing template
TA119 Leukaemia (lymphocytic) - fludarabine: Costing statement
CG67 Lipid modification: costing report
CG67 Lipid modification: costing template
CG30 Long-acting reversible contraception: cost impact report
CG30 Long-acting reversible contraception: cost template (England)
PH28 Looked-after children: costing report
CG147 Lower limb peripheral arterial disease: costing report
CG147 Lower limb peripheral arterial disease: costing template
CG97 Lower urinary tract symptoms: costing report
CG97 Lower urinary tract symptoms: costing template
CG121 Lung cancer: costing report
CG121 Lung cancer: costing template
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): costing statement
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib: costing statement
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - eroltinib (1st line): costing statement
TA192 Lung cancer (non-small-cell, first line) - gefitinib: costing template
TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed: costing template
TA162 Lung cancer (non-small-cell) - erlotinib: costing statement
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance): costing template
TA184 Lung cancer (small-cell) - topotecan: costing statement
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab: Costing template
TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: costing template
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: cost template
TA294 Macular degeneration (wet age-related) - aflibercept: costing template
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: costing template
TA274 Macular oedema (diabetic) - ranibizumab: costing template
TA229 Macular oedema (retinal vein occlusion) - dexamethasone: costing template
TA283 Macular oedema (retinal vein occlusion) - ranibizumab: costing template
PH19 Managing long-term sickness and incapacity for work: business case
PH19 Managing long-term sickness and incapacity for work: costing report
PH47 Managing overweight and obesity among children and young people: costing report
PH47 Managing overweight and obesity among children and young people: costing template
PH11 Maternal and child nutrition: costing statement
CG76 Medicines adherence: costing statement
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: costing template
TA268 Melanoma (stage III or IV) - ipilimumab: costing statement
PH16 Mental wellbeing and older people: costing report
TA135 Mesothelioma - pemetrexed disodium: costing statement
CG104 Metastatic malignant disease of unknown primary origin: costing statement
CG75 Metastatic spinal cord compression: costing report
CG75 Metastatic spinal cord compression: costing template
TA260 Migraine (chronic) - botulinum toxin type A: costing template
CG105 Motor neurone disease - non-invasive ventilation: costing report
CG105 Motor neurone disease - non-invasive ventilation: costing template
MTG10 MTG10 Pipeline embolisation device for the treatment of complex intracranial aneurysms: costing statement
MTG11 MTG11 Mega Soft Patient Return Electrode for use during monopolar electrosurgery: costing statement
MTG12 MTG12 EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing: costing template
MTG13 MTG13 WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: costing template
MTG14 MTG14 Ambu aScope2 for use in unexpected difficult airways: costing statement
MTG15 MTG15 Vision Amniotic Leak Detector to assess unexplained vaginal wetness in pregnancy: costing template
MTG16 MTG16 The E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta: costing statement
MTG17 MTG17 The Debrisoft monofilament debridement pad for use in acute or chronic wounds: costing report
MTG17 MTG17 The Debrisoft monofilament debridement pad for use in acute or chronic wounds: costing template
MTG1 MTG1 SeQuent Please balloon catheter for in-stent coronary restenosis: costing template and report
MTG3 MTG3 CardioQ-ODM (oesophageal Doppler monitor): costing template and report
MTG7 MTG7 Inditherm patient warming mattress for the prevention of inadvertent hypothermia: costing template
MTG8 MTG8 The VeriQ system for assessing graft flow during coronary artery bypass graft surgery: costing template
MTG9 MTG9 PleurX peritoneal catheter drainage system for vacuum assisted drainage of treatment-resistant recurrent malignant ascites: costing template
MTG2 MTG MoorLDI2 Burns Imager a laser Doppler blood flow imager for the assessment of burn wounds: costing template
TA228 Multiple myeloma (first line) - bortezomib and thalidomide: costing template
TA129 Multiple myeloma - bortezomib: costing template
TA171 Multiple myeloma - costing statement
CG129 Multiple pregnancy: costing report
CG129 Multiple pregnancy: costing template
TA303 Multiple sclerosis (relapsing) - teriflunomide: costing template
TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: costing template
TA127 Multiple sclerosis - natalizumab: costing template
TA218 Myelodysplastic syndromes - azacitidine: costing template
TA289 Myelofibrosis (splenomegaly, symptoms) - ruxolitinib: costing statement
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin: costing template
CG172 Myocardial infarction - secondary prevention: costing statement
CG167 Myocardial infarction with ST-segment elevation: costing report
CG167 Myocardial infarction with ST-segment elevation: costing template
PH52 Needle and syringe programmes: costing statement
CG98 Neonatal jaundice: costing report
CG98 Neonatal jaundice: costing template
CG98 Neonatal jaundice: costing template
CG173 Neuropathic pain - pharmacological management: costing statement
CG151 Neutropenic sepsis: costing report
CG151 Neutropenic sepsis: costing template
CG111 Nocturnal enuresis - the management of bedwetting in children and young people: costing statement
CG111 Nocturnal enuresis - the management of bedwetting in children and young people: costing template
TA306 Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: costing statement
CG32 Nutrition support in adults: costing report
CG32 Nutrition support in adults: costing template
CG43 Obesity: costing report
CG43 Obesity: costing template
PH42 Obesity - working with local communities: costing report
PH42 Obesity - working with local communities: costing template
CG31 Obsessive-compulsive disorder: cost impact report
CG31 Obsessive-compulsive disorder: cost template (England)
CG140 Opioids in palliative care: costing report
CG140 Opioids in palliative care: costing template
CG135 Organ donation: costing report
CG135 Organ donation: costing template
TA165 Organ preservation (renal) - machine perfusion and static storage: costing statement
CG177 Osteoarthritis: costing report
CG177 Osteoarthritis: costing template
CG146 Osteoporosis fragility fracture: costing report
CG146 Osteoporosis fragility fracture: local costing template
TA160 Osteoporosis - primary prevention: costing template
TA161 Osteoporosis - secondary prevention including strontium ranelate: costing template
TA204 Osteoporotic fractures - denosumab: costing statement
TA235 Osteosarcoma - mifamurtide: costing template
TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: costing statement
CG122 Ovarian cancer: costing statement
TA222 Ovarian cancer (relapsed) - trabectedin: costing statement
TA290 Overactive bladder - mirabegron: costing template
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation: costing template
CG35 Parkinson's disease: costing template
CG35 Parkinson's disease: national cost-impact report
CG138 Patient experience in adult NHS services: costing report
IPG196 Patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) via interventional procedures: Costing report
TA124 Pemetrexed for the treatment of non-small-cell lung cancer: costing statement
CG65 Perioperative hypothermia (inadvertent): costing report
CG65 Perioperative hypothermia (inadvertent): costing template
CG65 Perioperative hypothermia (inadvertent): costing template
TA223 Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate: costing template
CG125 Peritoneal dialysis: costing report
CG125 Peritoneal dialysis: costing template
PH44 Physical activity: brief advice for adults in primary care: costing report
PH44 Physical activity: brief advice for adults in primary care: costing template
PH8 Physical activity and the environment: cost report
CG37 Postnatal care: costing template
CG37 Postnatal care: national cost impact report
CG26 Post-traumatic stress disorder (PTSD): cost impact report
CG26 Post-traumatic stress disorder (PTSD): costing template (England)
CG110 Pregnancy and complex social factors: costing statement
PH14 Preventing the uptake of smoking by children and young people: costing statement
PH35 Preventing type 2 diabetes - population and community interventions: costing statement
PH38 Preventing type 2 diabetes - risk identification and interventions for individuals at high risk: costing report
PH38 Preventing type 2 diabetes - risk identification and interventions for individuals at high risk: costing template
PH30 Preventing unintentional injuries among under-15s in the home: costing report
PH30 Preventing unintentional injuries among under-15s in the home: costing template
PH31 Preventing unintentional road injuries among under-15s - road design: costing report
PH31 Preventing unintentional road injuries among under-15s - road design: costing template
PH36 Prevention and control of healthcare-associated infections: costing report
PH36 Prevention and control of healthcare-associated infections: costing template
PH25 prevention of cardiovascular disease: costing report
PH25 prevention of cardiovascular disease: costing template
PH3 Prevention of sexually transmitted infections and under 18 conceptions: costing report
PH3 Prevention of sexually transmitted infections and under 18 conceptions: costing template
PH22 Promoting mental wellbeing at work: business case
PH22 Promoting mental wellbeing at work: costing tool for employers
PH17 Promoting physical activity for children and young people: costing statement
PH13 Promoting physical activity in the workplace: business case
CG64 Prophylaxis against infective endocarditis: costing report
CG64 Prophylaxis against infective endocarditis: cost template
CG175 Prostate cancer: costing statement
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): costing template
TA255 Prostate cancer - cabazitaxel: costing statement
TA211 Prucalopride for chronic constipation in women: costing template
CG153 Psoriasis: costing report
CG153 Psoriasis: costing template
TA146 Psoriasis - adalimubab: cost template
TA103 Psoriasis - efalizumab and etanercept: Costing template and report
TA134 Psoriasis - infliximab: Costing template
TA180 Psoriasis - ustekinumab: costing statement
TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab: costing statement
TA220 Psoriatic arthritis - golimumab: costing statement
CG178 Psychosis and schizophrenia in adults: costing statement
CG155 Psychosis and schizophrenia in children and young people: costing report
CG155 Psychosis and schizophrenia in children and young people: costing template
CG120 Psychosis with coexisting substance misuse: costing statement
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban: costing template
PH26 Quitting smoking in pregnancy and following childbirth: costing template
PH21 Reducing the differences in the uptake of immunisations: costing statement
PH21 Reducing the differences in the uptake of immunisations: costing template
TA178 Renal cell carcinoma: costing statement
TA215 Renal cell carcinoma (first line metastatic) - pazopanib: costing statement
TA169 Renal cell carcinoma - sunitinib: costing template
TA99 Renal transplantation - immunosuppressive regimens for children and adolescents: costing statement
CG69 Respiratory tract infections: costing report
CG69 Respiratory tract infections: costing template
CG79 Rheumatoid arthritis: costing report
CG79 Rheumatoid arthritis: costing template
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: costing statement
TA280 Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234): costing statement
TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab: costing statement
TA186 Rheumatoid arthritis - certolizumab pegol: costing statement
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor and TA198 Rheumatoid arthritis - tocilizumab: costing template
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): costing statement
TA156 Routine antenatal anti-D prophylaxis for women who are rhesus D negative (review): costing statement
TA213 Schizophrenia - aripiprazole: costing statement
PH7 School-based interventions on alcohol: costing statement
PH23 School-based interventions to prevent smoking: costing template
CG112 Sedation in children and young people: costing report
CG133 Self-harm (longer term management): costing report
CG133 Self-harm (longer term management): costing template
CG136 Service user experience in adult mental health: costing report
CG143 Sickle cell acute painful episode: costing report
CG143 Sickle cell acute painful episode: costing template
PH32 Skin cancer prevention: information, resources and environmental changes: costing statement
CSGSTIM Skin tumours including melanoma: Costing Statement
TA139 Sleep apnoea - continuous positive airway pressure (CPAP): cost template
PH39 Smokeless tobacco cessation - South Asian communities: costing statement
PH48 Smoking cessation - acute, maternity and mental health services: costing statement
PH10 Smoking cessation services: costing report
PH10 Smoking cessation services: costing template
TA123 Smoking cessation - varenicline: costing template
PH40 Social and emotional wellbeing - early years: costing statement
PH12 Social and emotional wellbeing in primary education: costing statement
PH20 Social and emotional wellbeing in secondary education: costing statement
CG159 Social anxiety disorder: costing report
CG159 Social anxiety disorder: costing template
TA185 Soft tissue sarcoma - trabectedin: costing statement
CG145 Spasticity in children and young people: costing report
CG126 Stable angina: costing statement
PH29 Strategies to prevent unintentional injuries among under-15s: costing report
PH29 Strategies to prevent unintentional injuries among under-15s: costing template
CG68 Stroke: costing report
CG68 Stroke: costing template
TA264 Stroke (acute, ischaemic) - alteplase: costing template
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: costing statement
CG162 Stroke rehabilitation: costing report
CG162 Stroke rehabilitation: costing template
TA136 Structural neuroimaging in first-episode psychosis: costing statement
CG60 Surgical management of OME: costing report
CG60 Surgical management of OME: costing template
CG74 Surgical site infection: costing statement
PSG001 Technical patient safety solutions for medicines reconciliation on admission of adults to hospital: Costing template and report
PSG002 Technical patient safety solutions for prevention of ventilator-associated pneumonia in adults: costing statement
TA293 Thrombocytopenic purpura - eltrombopag: costing statement
TA221 Thrombocytopenic purpura - romiplostim: costing template
PH45 Tobacco harm-reduction approaches to smoking: costing report
PH45 Tobacco harm-reduction approaches to smoking: costing template
CG109 Transient loss of consciousness in adults and young people: costing statement
CG109 Transient loss of consciousness in adults and young people: costing template
CG117 Tuberculosis: costing report
CG117 Tuberculosis: costing statement
CG117 Tuberculosis: costing template
PH37 Tuberculosis - hard-to-reach groups: costing report
PH37 Tuberculosis - hard-to-reach groups: costing template
TA288 Type 2 diabetes - Dapagliflozin combination therapy: costing template
CG87 Type 2 diabetes - newer agents (a partial update of CG66): costing report
CG87 Type 2 diabetes - newer agents (a partial update of CG66): costing template
CG166 Ulcerative colitis: costing report
CG166 Ulcerative colitis: costing template
TA163 Ulcerative colitis (acute exacerbations) - infliximab: costing statement
TA140 Ulcerative colitis (subacute manifestations) - infliximab: costing statement
CG94 Unstable angina and NSTEMI: costing statement
CG148 Urinary incontinence in neurological disease: costing report
CG148 Urinary incontinence in neurological disease: costing template
CG171 Urinary incontinence in women: costing statement
CG54 Urinary tract infection in children: costing report
CG54 Urinary tract infection in children: costing template
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine: costing statement
CG168 Varicose veins in the legs: costing report
CG168 Varicose veins in the legs: costing template
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): costing statement
TA246 Venom anaphylaxis - immunotherapy pharmalgen: costing statement
CG144 Venous thromboembolic diseases: costing report
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: costing template
TA245 Venous thromboembolism - apixaban (hip and knee surgery): costing statement
TA157 Venous thromboembolism - dabigatran: costing statement
TA170 Venous thromboembolism - rivaroxaban: costing statement
TA279 Vertebral fractures - vertebroplasty and kyphoplasty: costing statement
CG25 Violence: cost impact report
CG25 Violence: costing template
TA297 Vitreomacular traction - ocriplasmin: costing template
PH41 Walking and cycling: costing report
PH41 Walking and cycling: costing template
PH27 Weight management before, during and after pregnancy: costing report
CG89 When to suspect child maltreatment: costing statement
PH5 Workplace interventions to promote smoking cessation: business case
PH5 Workplace interventions to promote smoking cessation: costing template

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.